Dr. Pande is a General Partner at Andreessen Horowitz ("a16z") and the founding General Partner of a16z's bio funds, where he leads the firm’s investments at the cross section of biology, computer science and engineering, including areas such as machine learning /compute in medicine (e.g., Freenome, Cardiogram, TwoXAR, BioAge), major game changing scientific advances (e.g., Apeel, Rigetti), and ways to fundamentally improve how health care is performed. A visionary leading the convergence of biology and computer science, Dr. Pande is the founder of the Folding@home Distributed Computing Project for disease research which pushes the boundaries of the development and application of computer science techniques into biology and medicine, in both fundamental research as well as the development of new therapeutics. In translating these advances, he has also been a founder and advisor to many startups in Silicon Valley.

Prior to joining Maverick in 2015, Mr. Bhattacharyya worked at Bessemer Venture Partners, Bain Capital Ventures, MinuteClinic (acquired by CVS), and Bain & Company. He has received broad recognition for his leadership, including Fortune Magazine's "40 under 40", Business Insider’s “30 leaders under 40 transforming healthcare”, and as a Global Shaper by the World Economic Forum. Mr. Bhattacharyya currently serves on the boards of one public company and several private companies, including Cityblock Health, Centivo, and HumanFirst. In addition, he serves as an advisor to the California Healthcare Foundation Innovation Fund, is an Aspen Institute Health Innovators Fellow and is a member of the Maverick Growth Investment Committee. 

Dylan Reid is a partner at Zetta Ventures, where he leads the firms life science practice, investing at the intersection of data, computing and biology. He is a founding investor and board member at a number of AI-native biotechs and software companies including Nabla Bio, Faro Health, Axiom, Nanite and Noetik. Before Zetta, he was founder and CEO of Matter, a venture-backed computer vision startup and an active angel investor in data, AI and robotics companies. 

Before co-founding Insamo, Dr. Tim Craven trained as a postdoctoral fellow in the lab of David Baker, 2023 Nobel Laureate in Chemistry. He earned his PhD under the guidance of Dr. Rich Bonneau, now Vice President of Machine Learning at Genentech, and previously served as a research associate at the FDA, NIST, and NASA. Over the past decade, Dr. Craven has been a leader in integrating advanced in silico design approaches with cutting-edge, ultra-high-throughput synthesis and testing technologies. At Insamo, his work focuses on pioneering the discovery of cyclic peptides to address unmet medical needs by providing innovative, orally available alternatives to traditional antibody therapeutics.

Ali Madani is a researcher and founder at the intersection of AI and Biology. He currently serves as the CEO of Profluent Bio, an AI startup in protein design. He previously led machine learning initiatives at Salesforce AI Research and most notably was the architect of the ProGen moonshot demonstrating the first usage of large language models for functional protein sequence generation. Ali completed his PhD at UC Berkeley. His scientific publications have appeared in NeurIPS, ICLR, Nature Biotechnology and have been covered by the New York Times, WSJ, Fortune, BBC, and others.